A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to see how effective JNJ-77242113 is in participants with
moderate to severe plaque psoriasis compared to placebo and deucravacitinib.